All anyone in obesity care seems to be talking about these days is GLP-1s, which is drawing plenty of attention among benefit brokers and advisers who are talking with their employer clients about offering and managing the cost of these drugs.
The historic weight loss, along with a high price tag, side effects, impact on lean body mass and weight regain are all hot topics. But as an eating disorder and obesity specialist, I am mystified about why we are not also talking about behavioral health — a known risk factor for and comorbidity of obesity. Those of us who have worked in obesity care for a long time know that undiagnosed or untreated behavioral health conditions are often at the heart of why obesity treatment doesn’t succeed. We can (and should) do more.
